Daily Pharmacy News

Get your free subscription started now. Just enter your email address below.

Insulin-Only iLet Bionic Pancreas in Cystic Fibrosis–Related Diabetes

Compared with usual care (UC), the iLet bionic pancreas (BP) improved glucose control without increasing hypoglycemia in adults with cystic fibrosis–related diabetes (CFRD), a study shows. “This may be an important therapeutic option for this patient population,” the authors conclude. Up to 50% of adults with cystic fibrosis have CFRD.

Participants (n = 20) randomly received 14 days each on the BP or UC without restrictions on diet or activity. Based on a primary outcome of the percentage of time the sensor-measured glucose concentrations were in the target range of 70–180 mg/dL (time in range [TIR]) on days 3–14 of each arm, the investigators found: “TIR was significantly higher in the BP arm than the UC arm (75 ± 11% vs. 62 ± 22%, P = 0.001). Mean CGM glucose was lower in the BP arm than in the UC arm (150 ± 19 vs. 171 ± 45 mg/dL, P = 0.007). There was no significant difference in percent time with sensor-measured glucose <54 mg/dL (0.27% vs. 0.36%, P = 1.0), although self-reported symptomatic hypoglycemia episodes were higher during the BP arm than the UC arm (0.7 vs. 0.4 median episodes per day, P = 0.01). No episodes of diabetic ketoacidosis or severe hypoglycemia occurred in either arm.”

Source: Diabetes Care